



HHS Public Access

Author manuscript

J Infect Dis Med. Author manuscript; available in PMC 2021 July 27.

Published in final edited form as:

J Infect Dis Med. 2017 ; 1(1): . doi:10.4172/2576-1420.1000102.

Identification of a Guinea Pig Fc γ Receptor that Exhibits Enhanced Binding to Afucosylated Human and Mouse IgG

Changchun Mao, Richard Near, Wenda Gao

Antagen Pharmaceuticals, Inc. Boston, MA 02118, USA

Abstract

Glyco-engineered recombinant antibodies are currently being developed as the next generation therapeutics to treat human diseases, including cancer, autoimmunity and infection. Antibodies lacking core fucosylation show great increase in affinity for Fc γ RIIIA, leading to an improved receptor-mediated effector function. While afucosyl human IgG1 exhibits 50–100-fold increase in antibody-mediated cellular cytotoxicity (ADCC), a key immune effector mechanism underlying the anti-cancer effect of some approved therapeutic antibodies, it is not clear whether such glyco-engineered antibodies would find similar use for infectious disease. Due to the species difference, human antibodies may have different binding properties towards corresponding IgG receptors from animals used for modeling infection and intoxication. During the course of studying a recombinant human IgG1 in neutralizing diphtheria toxin (DT) in Guinea pigs (*Cavia porcellus*), we identified a previously uncharacterized Guinea pig protein H0VDZ8 from UNIPROT database that shows high sequence homologies to human Fc γ RIIIA and mouse Fc γ RIV. This Fc γ receptor, which we named as gpFc γ RIV, also demonstrates functional similarity although not to the same extent as the human and mouse counterparts, in that it binds to afucosyl human and mouse IgG much stronger than to the wild type antibodies. Thus, Guinea pigs can be used to compare the efficacies of wild type vs. afucosyl anti-DT human IgG1 in toxin removal and animal protection. Molecular and functional characterization of human Fc γ RIIIA and mouse Fc γ RIV equivalents in other species could expand the list of preclinical animal models for testing afucosyl human antibodies in treating various human diseases.

Keywords

Immunoglobulin G; Fc Receptor; Afucosylation; Guinea Pig

Introduction

Monoclonal antibodies (Mabs) are being developed as therapeutics for treating various human diseases. The vast majority of marketed IgG Mabs are produced in mammalian cells, especially Chinese hamster ovary (CHO) cells. IgG1 antibodies produced from wild type CHO cells have a fucose residue in a 1,6 linkage to the first GlcNAc of the oligosaccharide

Corresponding author's contact information: Corresponding author: Dr. Wenda Gao, Ph.D., Mailing Address: Antagen Pharmaceuticals, Inc., 650 Albany St., STE 112, Boston, MA 02118, USA, Phone: 617-638-0315, Fax: 617-638-7140, wendagao01@gmail.com.

core (“core fucosylation”) in their bi-antenna glycan attached to asparagine (Asn) residue 297 in the Fc region. It has been well established by many laboratories that the addition of core fucose diminishes the affinity of IgG Fc to the human Fc γ R11A receptor expressed on natural killer cells, macrophages, neutrophils, and other immune cells. As a result, IgG molecules lacking a core fucose residue bind with 50-fold enhanced affinity to Fc γ R11A and exhibit 50–100-fold greater cellular immune functions, for example, antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) [1].

Currently, afucosyl antibodies with enhanced ADCC towards target cells are mainly being pursued in the immuno-oncology area. For example, Mogamulizumab is an afucosyl humanized Mab targeting CC chemokine receptor 4 (CCR4), approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukaemia-lymphoma (ATL) [2]. Obinutuzumab against CD20 is the second afucosyl Mab approved by US FDA in 2013 for treating B cell lymphoma [3]. Besides these two approved, more afucosyl antibodies are in the research pipeline, and the pharmaceutical industry has recognized the advantages of fucose-free therapeutic antibodies [3]. While the benefits of afucosyl Mabs in cancer immunotherapy are obvious, so far there are only two reports in infectious disease area supporting their potential application, where afucosyl antiviral antibodies show enhanced cell-mediated antiviral potency against the HIV and Ebola viruses [4, 5].

The main reason for this deficiency is due to the lack of knowledge on the binding properties of human IgGs with or without fucose towards corresponding antibody receptors from animals used for modeling infection and intoxication. Among the human Fc γ receptors, only Fc γ R11 is sensitive to IgG defucosylation. In mice, mFc γ R1V is regarded as the functional homologue of hFc γ R11A. Accordingly, only mFc γ R1V is sensitive to IgG defucosylation among all the murine Fc γ receptors ([6] and our unpublished observation). Little is known on the counterparts of hFc γ R11A and mFc γ R1V in other species, as well as their binding sensitivity towards afucosyl antibodies.

During the course of studying a human anti-diphtheria toxin IgG1 Mab in Guinea pigs (*Cavia porcellus*), we first asked: 1) whether hIgG1 can bind to Guinea pig Fc γ R, and 2) whether there is an equivalent of hFc γ R11A and mFc γ R1V in Guinea pigs that exhibits enhanced binding to afucosyl hIgG1. Our studies show that a previously uncharacterized Guinea pig protein H0VDZ8 from UNIPROT database is a structural and functional homologue to human Fc γ R11A and mouse Fc γ R1V.

Materials and Methods

Cell line generation:

CHO cell lines expressing the functional hFc γ R11A, mFc γ R1V or gpFc γ R1V complexes on the cell surface were generated with the “Toggle-In” CHO system (Antigen Pharmaceuticals, Inc., Boston, MA). The establishment of the anchor “Toggle-In” CHO cell line and the construction of pTOG3 and pTOG4 expression vectors with alternate use of Hygromycin B and Puromycin as selection markers will be published in more detail elsewhere. Briefly, an anchor “Toggle-In” CHO cell line was selected by FACS sorting on d1EGFP expression at a CHO genomic “hot-spot”. Several genes involved in enhancing

protein expression, e.g., SRP54, SRP9, SRP14, ERO1-L and FGF9 were sequentially integrated at this “hot-spot” by replacing d1EGFP with Cre-LoxP recombination-mediated cassette exchange (RMCE). A CHO cell line thus generated is named as the master “Toggle-In” line, which has been used for establishing other cell line models. Herein for example, human FcR common γ chain in pTOG4 was first transfected into the master “Toggle-In” line, and selected with Puromycin (10 $\mu\text{g}/\text{mL}$). An FcR γ -positive clone was picked and further transfected with hFc γ RIIIA-V158, mFc γ RIV or gpFc γ RIV, all cloned in pTOG3, respectively, and selected with Hygromycin B (1 mg/mL). Single CHO clones of double transfectants were screened and confirmed by FACS staining with hIgG1 or mIgG2a.

Expression of wild type and afucosyl antibodies:

A ScFv-hIgG1 construct, where its ScFv part utilizes anti-TNF α Humira sequence to fuse with human IgG1 Fc, was cloned into pDirect4.0 expression vector (Antagen), and transfected into either wild type or proprietary Fut8 $^{-/-}$ CHO-K1 cells (Antagen). This Fut8 $^{-/-}$ CHO cell line was established in-house with TALEN technology. Detailed method and genomic sequences of the two TALEN-targeted Fut8 alleles will be disclosed elsewhere. A mouse hybridoma secreting IgG2a antibody (PK136, ATCC, Manassas, Virginia) against mouse NK1.1 was transfected with two CRISPR constructs targeting the mouse Fut8 gene (Antagen). The Fut8 $^{-/-}$ CHO or hybridoma cells were selected by MACS depletion of fucose-positive cells, and confirmed by negative staining with FITC-labeled *Lens culinaris* agglutinin (LCA, Vector Laboratories, Inc., Burlingame, CA), recognizing the α -1,6 fucosylated tri-mannosyl core structure on N-glycans on the cell surface.

Comparing wild type and afucosyl antibodies in binding to Fc γ R:

Both CHO-derived wild type and afucosyl hIgG1, as well as hybridoma-derived wild type and afucosyl mIgG2a, were purified with Protein A column from culture supernatants. Protein concentrations were determined by OD280, and titrated amounts of wild type and afucosyl antibodies were assayed for receptor binding with goat anti-human or mouse secondary antibody in flow cytometry, using CHO cell lines expressing hFc γ RIIIA, mFc γ RIV or gpFc γ RIV.

Results and Discussion

To search for Guinea pig homologue(s) of hFc γ RIIIA and mFc γ RIV, we blasted UNIPROT database and found a few candidate Guinea pig proteins that show various homologies. One uncharacterized protein H0VDZ8 that has not been assigned a gene name shows the highest homologies: 55.3% identical and 72.5% similar amino acids with hFc γ RIIIA; 54.9% identical and 71.4% similar amino acids with mFc γ RIV (Figure 1). H0VDZ8 could be the potential Guinea pig equivalent of hFc γ RIIIA and mFc γ RIV.

Based on its amino acid sequence, we ordered full gene synthesis for H0VDZ8 as “gpFc γ RIV” with CHO codon optimization (Integrated DNA Technologies, Inc., Coralville, Iowa), and cloned it into the pTOG3 vector (Antagen). As FcR common γ chain co-expression is required for proper protein folding and cell surface display of hFc γ RIIIA or mFc γ RIV, we took the advantage of our “Toggle-In” system (Antagen), where Cre-LoxP

based sequential integration of exogenous genes into the same genomic locus is exploited for isogenic co-expression of the hFc γ R1IIIA+hFcR γ , mFc γ R1V+hFcR γ or gpFc γ R1V+hFcR γ complex (See Methods).

When titrated amounts of wild type and afucosyl hIgG1 were added to hFc γ R1IIIA-V158 expressing CHO cells, afucosyl hIgG1 demonstrated much better binding than wild type hIgG1. The EC₅₀ of afucosyl hIgG1 binding to hFc γ R1IIIA-V158 is about 200 ng/mL (1.25 nM), whereas that of the wild type hIgG1 is >2000 ng/mL (12.5 nM) (Figure 2, **upper left panel**). We estimate that by our method, there is >10–20-fold increase in hIgG1 binding to hFc γ R1IIIA-V158 after defucosylation. Mouse IgG2a did not show any binding to hFc γ R1IIIA (Figure 2, **lower left panel**), emphasizing that species difference will have to be taken into consideration when directly testing *in vitro* ADCC activities of mouse antibodies using hFc γ R1IIIA-expressing effector cells.

Interestingly, when wild type and afucosyl hIgG1 or mIgG2a antibodies were added to mFc γ R1V-expressing CHO cells, very similar binding patterns were obtained (Figure 2, **upper and lower middle panel**). This suggests that murine immune system could largely recapitulate the benefits of hIgG1 defucosylation. In other words, to demonstrate the enhanced therapeutic values of afucosylated humanized murine antibody (hIgG1 isotype) in mouse models of disease, researchers can directly take the advantage of CRISPR knockout of mouse Fut8 gene in hybridoma, and compare hybridoma-derived wild type and afucosyl parental mouse antibodies if they are of ADCC-enabling IgG2a/2b/2c isotypes. This could be an alternative to cloning the VH VL genes from the hybridoma and expressing the chimeric antibody genes with hIgG1 Fc in wild type and Fut8^{-/-} CHO cells.

However, the binding of hIgG1 to gpFc γ R1V does not show much enhancement after defucosylation (Figure 2, **upper right panel**). We repeated the assay and got very similar results: The EC₅₀ of afucosyl hIgG1 binding to gpFc γ R1V is about 289.3 ng/mL (1.81 nM), whereas that of the wild type hIgG1 is 712.1 ng/mL (4.45 nM) (data not shown), a mere 2.5 fold enhancement. For mIgG2a, although it does not bind to hFc γ R1IIIA-V158, its binding to gpFc γ R1V is dramatically enhanced after defucosylation (Figure 2, **lower right panel**).

Our studies answered the initial questions that hIgG1 can bind to Guinea pig Fc γ R and H0VDZ8 is a structural and functional homologue to human Fc γ R1IIIA and mouse Fc γ R1V. In fact, based on the mean fluorescence intensity (MFI) data in flow cytometry, the binding affinity of hIgG1 to this gpFc γ R1V is about 100-fold and 10-fold over the binding affinity of hIgG1 to hFc γ R1IIIA and mFc γ R1V, respectively. We believe these are not due to the cell line differences in receptor surface expression because of integration site and copy number variation seen in the conventional transfection method, as our “Toggle-In” system can eliminate such factors by site-specific isogenic expression of exogenous genes with equal copy number. Perhaps also due to this stronger base line binding of hIgG1 to gpFc γ R1V, the difference between the wild type and the afucosyl forms of hIgG1 in binding to gpFc γ R1V is not as dramatic. Therefore, the benefit of afucosyl hIgG1 in Guinea pig model could be under-manifested as in humans. From proof-of-concept point of view, it remains to be tested whether murinized human therapeutic IgG with mIgG2a/b/c Fc tail would better exemplify the benefits of afucosyl antibodies in disease models where Guinea pigs are used as host.

Acknowledgement

This study is supported by SBIR contracts from CDC (200-2014-M-59655, 2015-N-17179) and NIH/NIDA (HHSN271201100015C).

Abbreviations:

CHO	Chinese hamster ovary
ADCC	Antibody-mediated cellular cytotoxicity
ADCP	antibody-dependent cellular phagocytosis
Fut8	Alpha-(1,6)-fucosyltransferase 8
TALEN	Transcription activator-like effector nuclease

Reference

1. Listinsky JJ, Siegal GP, Listinsky CM (2013) Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model. *Anticancer Drugs* 24: 219–227. <http://www.ncbi.nlm.nih.gov/pubmed/23059384> [PubMed: 23059384]
2. Beck A, Reichert JM (2012) Marketing approval of mogamulizumab: a triumph for glyco-engineering. *MAbs* 4: 419–425. <http://www.ncbi.nlm.nih.gov/pubmed/22699226> [PubMed: 22699226]
3. Small S (2013) Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia. *Clin Adv Hematol Oncol* 11: 809–810. <http://www.ncbi.nlm.nih.gov/pubmed/25016628>
4. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, et al. (2010) Fc-glycosylation influences Fc γ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. *J Immunol* 185: 6876–6882. <http://www.ncbi.nlm.nih.gov/pubmed/21041724> [PubMed: 21041724]
5. Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. *Proc Natl Acad Sci USA* 108: 20690–20694. <http://www.ncbi.nlm.nih.gov/pubmed/22143789> [PubMed: 22143789]
6. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. *Science* 310: 1510–1512. <http://www.ncbi.nlm.nih.gov/pubmed/16322460> [PubMed: 16322460]

H0VDZ8	H0VDZ8_CAVPO	37	MWHLPPSALLLLISSVTKAADPSKAVVLLDPPWVRVLTDDNVTLTCQGAYPPENNNTRW
P08637	FCG3A_HUMAN	1	MW LL P+ALLLL+S+ + D KAVV L+P W RVL D+VTL CQGAY PE+N+T+W
H0VDZ8	H0VDZ8_CAVPO	97	MWQLLLPTALLLLVSAGMRTELDPKAVVFLPEQWYRVLEKDSVTLKQCQAYSPEDNSTQW
P08637	FCG3A_HUMAN	61	FHNGTHIVGSQAPSYLISGIKVENSGKYQCQTDLSPLSDSVQLQVHADWLVLTQTSKWV FQ
H0VDZ8	H0VDZ8_CAVPO	157	FHN + ++ SQA SY I V++SG+Y+CQT+LS LSD VQL+VH WL+LQ +WV+FHNES-LISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFK
P08637	FCG3A_HUMAN	120	KGESIRLRCHSWKNKRLYKVTYLQNGKPKKFFHNNSEFHIPEATVNHTGSYYCRGLIGHN
H0VDZ8	H0VDZ8_CAVPO	217	+ + I LRCHSWKN L+KVTYLQNGK +K+FH+NS+F+IP+AT+ +GSY+CRGL G
P08637	FCG3A_HUMAN	180	EEDPIHLRCHSWKN TALHKVTYLQNGKGRKYFHNSDFYIPKATLKDSGSYFCRGLFGSK
H0VDZ8	H0VDZ8_CAVPO	277	NKSSGIVAITFQADFAGPSIAPLFLWQQIAFCLMMGLLFAVD TGLYFFVRRDLRRSMVH
P08637	FCG3A_HUMAN	240	N SS V IT A +I+ FP Q++FCL+M LLFAVD TGLYF V+ ++R S
H0VDZ8	H0VDZ8_CAVPO	277	NVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVD TGLYFSVKTNIRSTRD
P08637	FCG3A_HUMAN	240	KEEYNFKW-SQAQDK +++ FKW QDK WKDHKFKWRKDPQDK
H0VDZ8	H0VDZ8_CAVPO	37	MWHLPPSALLLLISSVTKAADPSKAVVLLDPPWVRVLTDDNVTLTCQGAYPPENNNTRW
Q8R477	Q8R477_MOUSE	1	MW LL P+AL+L S +A KAVV LDP WVRVL +D+VTL CQG + PE+N+ +W
H0VDZ8	H0VDZ8_CAVPO	97	MWQLLLPTALVLTAFSGIQAG-LQKAVVNLDPKWVRVLEEDSVTLRCQGTFSPEDNSIKW
Q8R477	Q8R477_MOUSE	60	FHNGTHIVGSQAPSYLISGIKVENSGKYQCQTDLSPLSDSVQLQVHADWLVLTQTSKWV FQ
H0VDZ8	H0VDZ8_CAVPO	157	FHN + ++ Q +Y+I +V++SG Y+CQT LS +SD VQL+VH WL+LQT+KW+ FQ
Q8R477	Q8R477_MOUSE	119	FHNES-LIPHQDANYVIQSARVKDSGMRYCQTALSTISDPVQLEVHMGWLLLQTTKWLFQ
H0VDZ8	H0VDZ8_CAVPO	217	KGESIRLRCHSWKNKRLYKVTYLQNGKPKKFFHNNSEFHIPEATVNHTGSYYCRGLIGHN
Q8R477	Q8R477_MOUSE	179	+G+ I LRCHSW+N+ + KVTYLQNGK KK+FH NSE IP+AT N +GSY+CRGLIGHN
H0VDZ8	H0VDZ8_CAVPO	277	EGDPIHLRCHSWQNRPVKVTY LQNGK GK KYFHENSELPIPKATHNDSGSYFCRGLIGHN
Q8R477	Q8R477_MOUSE	235	NKSSGIVAITFQADFAGPSIAPLFLWQQIAFCLMMGLLFAVD TGLYFFVRRDLRRSMVH
H0VDZ8	H0VDZ8_CAVPO	277	NKSS +F+ P +FP W QI FCL++GLLFA+DT LYF VRR L+ +
Q8R477	Q8R477_MOUSE	235	NKSSA----SFRISLGDGPGSPSMFPPWHQITFCLLIGLLFAIDTVLYFSVRRGLQSPVAD
H0VDZ8	H0VDZ8_CAVPO	277	KEEYNFKWS-QAQDK
Q8R477	Q8R477_MOUSE	235	EE +WS + QDK YEYPKIQWSKEPQDK

Figure 1.
Alignment of Guinea pig protein H0VDZ8 with hFcγRIIIA (P08637, upper) or mFcγRIV (Q8R477, lower).




Figure 2.

Flow cytometry analysis of binding of wild type or afucosyl hIgG1 (upper) and mIgG2a (lower) to hFc γ RIIIA, mFc γ RIV or gpFc γ RIV (H0VDZ8). Data are representative of two similar experiments.